Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/201067
Title: Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
Author: Fernández Velasco, José I.
Monreal, Enric
Kuhle, Jens
Meca Lallana, Virginia
Meca Lallana, José E.
Izquierdo, Guillermo
Oreja Guevara, Celia
Gascón Gimenez, Francisco
Sainz de la Maza, Susana
Walo Delgado, Paulette E.
Lapuente Suanzes, Paloma
Maceski, Aleksandra
Rodriguez Martín, Eulalia
Roldán, Ernesto
Villarrubia, Noelia
Saiz Hinarejos, Albert
Blanco, Yolanda
Diaz Pérez, Carolina
Valero López, Gabriel
Díaz Díaz, Judit
Aladro, Yolanda
Brieva, Luis
Iñíguez, Cristina
González Suárez, Inés
Rodríguez de Antonio, Luis A.
García Domínguez, José M.
Sabin, Julia
Llufriu Duran, Sara
Masjuan, Jaime
Costa Frossard, Lucienne
Villar, Luisa M.
Keywords: Esclerosi múltiple
Imatges per ressonància magnètica
Multiple sclerosis
Magnetic resonance imaging
Issue Date: 21-Mar-2022
Abstract: To ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Ten Gd+ (62.5%) and 41 Gd- patients (77.4%) showed non-evidence of disease activity (NEDA) defined as no disability progression or new MRI lesions after 1 year of treatment. Blood immune cell subsets were characterized by flow cytometry, serum immunoglobulins by nephelometry, and serum neurofilament light-chains (sNfL) by SIMOA. Statistical analyses were corrected with the Bonferroni formula.More than 60% of patients reached NEDA after a year of treatment, regardless of their baseline characteristics. In Gd+ patients, it associated with a low repopulation rate of inflammatory B cells accompanied by a reduction of sNfL values 6 months after their first ocrelizumab dose. Patients in Gd- group also had low B cell numbers and sNfL values 6 months after initiating treatment, independent of their treatment response. In these patients, NEDA status was associated with a tolerogenic remodeling of the T and innate immune cell compartments, and with a clear increase of serum IgA levels.Baseline inflammation influences which immunological pathways predominate in patients with PPMS. Inflammatory B cells played a pivotal role in the Gd+ group and inflammatory T and innate immune cells in Gd- patients. B cell depletion can modulate both mechanisms.Copyright © 2022 Fernández-Velasco, Monreal, Kuhle, Meca-Lallana, Meca-Lallana, Izquierdo, Oreja-Guevara, Gascón-Giménez, Sainz de la Maza, Walo-Delgado, Lapuente-Suanzes, Maceski, Rodríguez-Martín, Roldán, Villarrubia, Saiz, Blanco, Diaz-Pérez, Valero-López, Diaz-Diaz, Aladro, Brieva, Íñiguez, González-Suárez, Rodríguez de Antonio, García-Domínguez, Sabin, Llufriu, Masjuan, Costa-Frossard and Villar.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.842354
It is part of: Frontiers In Immunology, 2022, vol. 13
URI: http://hdl.handle.net/2445/201067
Related resource: https://doi.org/10.3389/fimmu.2022.842354
ISSN: 1664-3224
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)



This item is licensed under a Creative Commons License Creative Commons